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Abstract Congenital cytomegalovirus (CMV) infection has
potentially severe consequences in newborns. The testing of
pregnant women for CMV-specific antibodies may be useful
for the identification of women at risk of transmitting the
infection to the fetus. The determination of CMV IgG avidity
helps to establish the timing of infection as IgG avidity ma-
tures during the course of infection. This study examines the
performance of the Elecsys® CMV IgG Avidity assay using
preselected samples from patients at different phases of CMV
infection. The Elecsys® CMV IgG Avidity assay was tested at
three sites using sequential samples from patients with recent
primary CMV infection, as well as single samples from pa-
tients with recent primary or past CMV infection. The
depending on the consideration of gray-zone avidity values.
Single samples from recent primary or past infection showed
similar distributions of avidity results. The Elecsys® CMV
IgG Avidity assay results are in agreement with preselected
samples from patients with primary or past CMV infection,
showing that the test is an adequate predictor of the phase of
infection.
Introduction
Congenital cytomegalovirus (CMV) infection has potentially
severe consequences in the newborn, which include neuro-
sensory hearing loss, mental retardation, impaired physical
development, and, in some cases, neonatal death [1]. The
highest risk of transmission of CMV from mother to fetus is
associated with primary infection, and the risk of severe
abnormalities is highest when primary maternal infection
occurs in the periconceptional period or the first trimester of
pregnancy [2–4]. This risk decreases throughout pregnancy,
although the chance of CMV vertical transmission is greatest
in the third trimester [3–5]. Maternal recurrent CMV infection
(i.e., a reinfection with a new CMV strain or reactivation of a
latent strain) can also result in congenital CMV [6]. However,
only rarely do non-primary infections lead to severe clinical
symptoms.
The clinical diagnosis of maternal CMV infection is diffi-
cult, as symptoms are non-specific or absent in many cases.
Hence, serological testing for CMV-specific immunoglobulin
(Ig) M and IgG is required. IgM antibody is produced in the
early phase of infection, and then declines in the following
months, whereas IgG antibody levels increase gradually but
can persist for several decades. This means that a subject who
tests positive for CMV IgG only has been infected in the past.
The scenario is much more complicated, however, if a subject
tests positive for both IgM and IgG; in such a case, it is
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Elecsys® assay discriminated well between early (low avid-
ity) and late (high avidity) phases of infection in sequential
serum samples. Overall, 98.8 % of low-avidity samples
corresponded to infection onset <180 days before sampling
and 77.8 % of all high-avidity results corresponded to infec-
tion onset >90 days before sampling. The assay’s sensitivity
was 90–97 %, with specificity ranging from 89 to 100 %,
impossible to discriminate primary infection from a non-
primary infection on a single serum sample [7]. Measuring
the overall binding strength or avidity of CMV-specific IgG
can help to make this distinction: primary infection generally
will show low-avidity IgG in the early phases of infection,
gradually maturing to high-avidity IgG approximately 22–
24 weeks after infection onset [8, 9].
Ideally, assays designed to measure CMV IgG avidity
should detect virus-specific IgG of low avidity in serum
samples taken early after the onset (i.e., in the first 2–3months)
and IgG of high avidity in samples taken 6 or more months
after infection onset, with IgG of moderate avidity detectable
in between. However, a recent study showed that several
currently available CMV IgG avidity assays do not achieve
these ideal performance characteristics [10]. The aim of this
study was to evaluate the recently developed Elecsys® CMV
IgG Avidity assay, which is unique in that it uses a mixture of
viral recombinant proteins rather than whole CMVantigen.
Materials and methods
This study was carried out between March and July 2010 at
three centers in Europe: Pavia, Italy; Bologna, Italy; and Paris-
Clamart, France. Serum samples previously characterized at
each of the centers were reanalyzed using the Elecsys® CMV
IgM, IgG, and IgG Avidity assays.
Preselection of samples
Frozen sequential serum samples taken from 61 pregnant
women during routine clinical practice were reanalyzed at
the center in Pavia (n=180 in total). In 52 (85 %) of these
cases, the diagnosis had been made on the basis of IgG
seroconversion in the presence (33 cases) or absence of clin-
ical symptoms. The remaining nine cases (eight symptomatic)
had been diagnosed by CMV IgM kinetics (ETI-CYTOK-M
reverse assay; DiaSorin, Saluggia, Italy), CMV IgG avidity
(in-house CMV IgG avidity ELISA [11]), and CMV
DNAemia [12]. When possible, presumed dating of infection
onset was based on the presence of clinical symptoms and/or
abnormal laboratory findings. Otherwise, the date of onset
was arbitrarily set between the last IgG-negative and first
IgG-positive sample (median time lapse 42, range 10–
78 days).
Single frozen serum samples from subjects with primary
(n=100) and past CMV infections (n=50) were reanalyzed at
the center in Bologna. Primary infection had been confirmed
by clinical history as well as CMV IgM-positive and low
CMV IgG avidity results, positive DNAemia, and/or demon-
stration of seroconversion for CMV-specific antibodies. Past
infection had been determined by the absence of CMV IgM
and high CMV IgG avidity results. Negative IgM results were
confirmed with immunoblot testing [13]. In addition, 52 se-
quential serum samples from 16 patients with primary CMV
infection were also included in the study. Seven out of 16
(44 %) patients with primary CMV infection had symptoms
that could have been related to CMV infection in an immuno-
competent subject (fever and/or an increase in hepatic trans-
aminases). In this group, the onset of infection was based on
the appearance of symptoms. In the remaining nine asymp-
tomatic patients (56 %), the date of onset was estimated to be
20–30 days (range, 15–40 days) before the date of serocon-
version (for IgM or IgG), as previously reported [9]. For
preclassification, sera were tested using the Enzygnost®
CMV IgM assay and Enzygnost CMV IgG assay (Siemens
Healthcare Diagnostics, Deerfield, IL, USA) and an in-house
immunoblot for the detection of CMV-specific IgM [13].
CMV IgG avidity was tested with the Radim® Cytomegalo-
virus IgG Avidity EIAWELL assay (Radim, Pomezia, Italy)
[9].
The center in Paris-Clamart reanalyzed single frozen serum
samples from pregnant women with primary (n=25) and past
CMV infection (n=57), as well as 48 sequential frozen serum
samples from 14 pregnant women with primary CMV infec-
tion. The sequential samples had been taken monthly during
pregnancy and included first visit samples containing CMV
IgM with or without low-avidity CMV IgG and respective
follow-up samples. The onset of infection was estimated to be
15–31 days before the first IgG-positive result. Samples had
been preclassified using the Liaison® CMV IgG and CMV
IgM assays (DiaSorin, Saluggia, Italy). If CMV IgM and IgG
were both present, IgG avidity measurement was performed.
Low-avidity results obtained with the Liaison CMV IgG
avidity assay (DiaSorin, Saluggia, Italy) were confirmed using
an in-house ELISA and the VIDAS® CMV IgG Avidity assay
(bioMérieux, Marcy-L’Étoile, France).
Elecsys® CMVAvidity assay: principle, calculation,
and interpretation of results
The avidity assay consists of twomeasurements run in parallel
using separate aliquots of the sample. The first is a reference
measurement using undiluted sample or sample diluted as
described above. In brief, the sample is incubated with a
mixture of biotin- or ruthenium-labeled CMV-specific recom-
binant antigens to form sandwich complexes. Streptavidin-
coated paramagnetic microparticles are added, and complexes
are attracted to the solid phase by streptavidin–biotin interac-
tions and a magnetic field. Unbound reagents are washed out
of the system and bound antibody is detected by measuring
voltage-induced chemiluminescence from the ruthenium la-
bels. The second measurement follows the same reaction
principle, but is performed in the presence of Elecsys®
DilCMVAv buffer [0.8 M guanidine chloride, CMV-specific
antigen (recombinant, E. coli); MES buffer 50 mmol/L,
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pH 6.5; preservative], which disrupts the binding of low-
avidity IgG to CMV.
Testing with the Elecsys® CMV IgG Avidity assay is only
applicable in samples that report a positive result with the
Elecsys® CMV IgG assay. If an IgG result >500 U/mL is
obtained, the sample should be diluted 1:20 with Elecsys®
Diluent Universal prior to avidity determination.
The reference and DilCMVAv-treated measurement results
are used to manually calculate the ratio of high-avidity IgG
present in the sample, as follows:









Samples reporting %Avi values <45.0 indicated low-
avidity IgG and samples with %Avi ≥55.0 indicate high-
avidity IgG. Samples reporting %Avi ranging between 45.0
and 54.9 fall into the gray-zone and cannot be used to distin-
guish between past and active primary CMV infection. [14]
Data analyses
Results from the Elecsys® CMV IgG avidity assay in sequen-
tial samples from patients with primary CMV infection were
analyzed with respect to the percentage of samples that
contained low-avidity, gray-zone, or high-avidity IgG within
three time ranges: <90 days, 90–180 days, and >180 days after
the onset of infection/first bleed. Samples not tested due to
insufficient sample volume and samples with negative or
equivocal IgG results were excluded from the analysis. Single
samples from patients with primary or past CMV infection
from the Paris-Clamart and Bologna sites were presented as
multidot plots to show the distribution of avidity results using
the Elecsys® CMV IgG Avidity assay from each site and by
phase of infection. The sensitivity of the Elecsys® CMV IgG
Avidity assay was defined as the percentage of samples
predefined as representing a primary CMV infection that gave
low-avidity results, whereas the specificity was defined as the
percentage of predefined samples from past CMV infection
that gave high-avidity results.
Results
Sequential samples from patients with primary CMVinfection
In total, 246 sequential samples from patients with primary
CMV infection from the three centers were included in the
analysis. The distribution of CMV-specific IgG avidity results
is shown in Fig. 1. Good discrimination between the early
stages of infection (mainly low-avidity IgG results reported)
and several months after infection (mainly high-avidity IgG
results reported) was observed. There was some overlap in the
distribution of the 90–180 days time period samples: 49 %
showed low avidity, 29 % were equivocal, and 22 % showed
high avidity. The majority of the low-avidity results
corresponded with infection onset <90 days prior to the sam-
ple being taken, with only 1.2 % corresponding to infection
onset >180 days before sampling. Samples containing high-
avidity IgG corresponded to infection onset >90 days before
sampling in 77.8 % of cases.
Single samples from patients with primary or past CMV
infection
The distribution of CMV-specific IgG avidity results in single
samples from patients with primary or past CMV infection
from the centers in Paris-Clamart and Bologna is shown in
Fig. 2. The distribution of avidity results from the two centers
in both primary and past infection samples was very similar. A
clear distinction between the types of infection was observed,
with primary infection samples showing low-avidity IgG re-
sults and past infection samples showing high-avidity IgG
results. Discrepant results were relevant to high avidity ob-
tained in five samples collected from different cases of prima-
ry infection, and four low-avidity results were observed in the
past infection group of samples. Two of these four samples
were retested with a third avidity assay and gave high-avidity
results.
Assay sensitivity ranged from 91 to 97 % across the two
testing centers (Table 1), and these values were very similar
regardless of whether samples that fell into the gray-zone were
excluded or were considered low-avidity samples. On the
other hand, the specificity was slightly lower when samples
with gray-zone avidity values were included in the low-
avidity group (89.5 % in Paris-Clamart, 80.0 % in Bologna)
than when they were excluded (100.0 % in Paris-Clamart,
90.9 % in Bologna; Table 2).
Discussion
In this study, the performance of the Elecsys® CMV IgG
Avidity assay was evaluated on two groups of previously
characterized serum samples collected from subjects with
primary or past CMV infection, respectively. The results ap-
peared to correlate well with the sample classification.
In pregnancy, the most important requirement for a CMV
IgG avidity assay is to help in identifying or excluding a
primary infection occurring in the previous 3 months in wom-
en presenting with a positive CMV IgM result. To reflect this,
the sequential samples from all three centers were divided into
three time points: <90 days, 90–180 days, and >180 days after
the onset of infection. The majority of samples taken <90 days
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after infection onset were reported as containing low-avidity
CMV IgG and the majority of samples taken >180 days after
infection onset were reported as high-avidity CMV IgG by the
Elecsys® CMV IgG Avidity assay. A mixture of low-avidity,
gray-zone, and high-avidity results (49 %, 29 %, and 22 % of
samples, respectively) were observed in samples taken 90–
180 days after infection onset. The latter observation is con-
sistent with the fact that the kinetics of the IgG avidity matu-
ration process is likely to vary between individuals. Because
of this, low-avidity IgG can be detected later than 90 days after
infection onset for some patients [8, 9], with a delay in IgG
avidity maturation specifically observed in some pregnant
women. This could explain why low-avidity results were
reported for almost half of the samples taken 90–180 days
after infection onset in this study. Differences in the method
used to ascertain the date of infection onset at the three sites in
this study may also contribute to this variation.
Using this assay, a primary infection would be identified
with 95 % certainty, and a past infection would be identified
with 92 % certainty. It should be noted that, in normal clinical
practice, CMV IgG avidity measurements are only performed
if patients also report a positive IgM result, so if the samples
from this study taken >180 days after infection onset were the
only samples that were tested for each of the patients, 15/24
samples would not actually have been assessed for CMV IgG
avidity, as they were IgM negative.
The single samples from patients with primary or past
CMV infection were analyzed separately because it is much
more difficult to accurately date the presumed onset of
Fig. 1 Distribution of CMV-specific IgG results from sequential samples
at several time points after infection
Fig. 2 Distribution of CMV-specific IgG avidity results in single samples
from patients with primary and past infections. *Three samples not shown
due to avidity results >100 %. **Two samples not shown due to avidity
results >100 %
Table 1 Results from single samples from primary infection
Paris-Clamart Bologna
Samples tested 25 93a
Low avidity 21 74
Gray-zone 2 16
High avidity 2 3
Sensitivityb 91.30 % 96.10 %
95 % CIb 79.96–98.93 89.03–99.19
Sensitivityc 92.00 % 96.80 %
95 % CIc 73.97–99.02 90.86–99.33
a Seven samples excluded as they were IgG-negative with the Elecsys
CMV IgG assay
b Results falling within the gray-zone were excluded from the analysis
c Results falling within the gray-zone were considered as low avidity for
the analysis
Table 2 Results from single samples from past infection
Paris-Clamart Bologna
Samples tested 57 50
Low avidity 0 4
Gray-zone 6 6
High avidity 51 40
Specificitya 100.00 % 90.90 %
95 % CIa 93.02–100.00 78.33–97.47
Specificityb 89.50 % 80.00 %
95 % CIb 78.48–96.04 66.28–89.97
a Results falling within the gray-zone were excluded from the analysis
b Results falling within the gray-zone were considered as low avidity for
the analysis
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infection when only single samples are available. Overall, the
Elecsys® CMV IgG Avidity assay reported low-avidity IgG
in≈95 % of samples from primary infection and high-avidity
IgG in≈95 % of samples (≈85 % if equivocal results are
considered low) from past infection.
Data from other studies indicate that the results from CMV
IgG avidity assays vary greatly. Differences have been ob-
served in the ability of assays to correctly detect or exclude
recent infection [15, 16] and in the results reported by different
assays for the same samples. A comprehensive study by
Revello et al. [10] using eight commercial CMV IgG avidity
assays to test 198 samples found that none of the results were
the same for all assays. Furthermore, the same qualitative
result obtained with at least five assays was only reported
for 59.6 % of the samples, highlighting the lack of standard-
ization between the assays and the need to test sequential
follow-up samples with the same assay. In addition, delayed
IgG avidity maturation has been observed in pregnant women
with CMV [2, 8, 9, 15] or toxoplasma [17] infections, thus
potentially leading to misclassification of the actual phase of
infection. Finally, changing the cutoff level may be necessary
in order to improve performance, as recently reported for the
VIDAS assay [18].
In conclusion, the results obtained using the Elecsys®
CMV IgG Avidity assay are in agreement with preselected
samples classified as primary or past CMV infection. There-
fore, the assay appears suitable for use in clinical practice.
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